[go: up one dir, main page]

BRPI0417011A - composições compreendendo compostos orgánicos - Google Patents

composições compreendendo compostos orgánicos

Info

Publication number
BRPI0417011A
BRPI0417011A BRPI0417011-3A BRPI0417011A BRPI0417011A BR PI0417011 A BRPI0417011 A BR PI0417011A BR PI0417011 A BRPI0417011 A BR PI0417011A BR PI0417011 A BRPI0417011 A BR PI0417011A
Authority
BR
Brazil
Prior art keywords
compositions
organic compounds
phase
core
hmg
Prior art date
Application number
BRPI0417011-3A
Other languages
English (en)
Inventor
Sabine Dessetbrethes
Andreas Meyer
Joerg Ogorka
Jean-Pierre Cassiere
Armelle Decouz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0417011A publication Critical patent/BRPI0417011A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçõES COMPREENDENDO COMPOSTOS ORGáNICOS". A presente invenção refere-se às composições farmacêuticas para liberação contínua compreendendo como ingrediente ativo um inibidor de HMG-CoA redutase ou um sal farmaceuticamente aceitável deste, a dita composição compreendendo um núcleo que consiste em uma fase interior (interna) e uma fase exterior (externa) em que a fase exterior não compreende um formador de matriz e em que o núcleo é revestido primeiro com um revestimento de filme não-funcional e depois com um revestimento entérico.
BRPI0417011-3A 2003-11-26 2004-11-25 composições compreendendo compostos orgánicos BRPI0417011A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52537303P 2003-11-26 2003-11-26
PCT/EP2004/013419 WO2005051346A2 (en) 2003-11-26 2004-11-25 Compositions comprising organic compounds

Publications (1)

Publication Number Publication Date
BRPI0417011A true BRPI0417011A (pt) 2007-02-21

Family

ID=34632977

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417011-3A BRPI0417011A (pt) 2003-11-26 2004-11-25 composições compreendendo compostos orgánicos

Country Status (15)

Country Link
US (1) US20070218134A1 (pt)
EP (1) EP1689398A2 (pt)
JP (1) JP2007512287A (pt)
KR (1) KR20060118507A (pt)
CN (1) CN1905880A (pt)
AR (1) AR046458A1 (pt)
AU (1) AU2004292768B2 (pt)
BR (1) BRPI0417011A (pt)
CA (1) CA2546244A1 (pt)
MX (1) MXPA06005953A (pt)
MY (1) MY147202A (pt)
PE (1) PE20050588A1 (pt)
RU (1) RU2006122630A (pt)
TW (1) TW200534876A (pt)
WO (1) WO2005051346A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048413B2 (en) * 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
CN102048701B (zh) * 2010-11-29 2013-01-09 青岛黄海制药有限责任公司 一种匹伐他汀钙肠溶缓释微丸制剂及其制备方法
JP5988963B2 (ja) * 2011-04-12 2016-09-07 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
WO2012153181A1 (en) * 2011-05-11 2012-11-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
ES2821766T3 (es) 2013-02-22 2021-04-27 Zeria Pharm Co Ltd Comprimido con recubrimiento entérico
JP6667526B2 (ja) * 2014-08-13 2020-03-18 シーダーズ−サイナイ メディカル センター 抗メタン生成組成物及びその使用
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
EP3641732A1 (en) * 2017-06-21 2020-04-29 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
CN111053752A (zh) * 2018-10-16 2020-04-24 南京卓康医药科技有限公司 一种稳定的匹伐他汀钙的肠溶片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
CN1440283A (zh) * 2000-04-12 2003-09-03 诺瓦提斯公司 有机化合物的联合形式
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
CN100430405C (zh) * 2001-08-16 2008-11-05 特瓦制药工业有限公司 制备他汀类的钙盐形式的方法
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike

Also Published As

Publication number Publication date
CA2546244A1 (en) 2005-06-09
MXPA06005953A (es) 2006-07-06
AR046458A1 (es) 2005-12-07
KR20060118507A (ko) 2006-11-23
JP2007512287A (ja) 2007-05-17
MY147202A (en) 2012-11-14
WO2005051346A2 (en) 2005-06-09
CN1905880A (zh) 2007-01-31
TW200534876A (en) 2005-11-01
WO2005051346A3 (en) 2005-08-25
PE20050588A1 (es) 2005-09-05
RU2006122630A (ru) 2008-01-10
AU2004292768B2 (en) 2009-04-02
US20070218134A1 (en) 2007-09-20
EP1689398A2 (en) 2006-08-16
AU2004292768A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
BRPI0510419A (pt) formulação e método de comprimido revestido
BRPI0519342A2 (pt) composiÇÕes de revestimento aquosas
BRPI0719395C1 (pt) tablete revestido de filme
BRPI0417011A (pt) composições compreendendo compostos orgánicos
BR0111754A (pt) Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
CL2007003000A1 (es) Compuestos derivados de biaril eter urea; composicion farmaceutica que los contienen; y su uso para el tratamiento de enfermedades o afecciones asociadas a la actividad de amida hidrolasa de acidos grasos (faah).
UY30762A1 (es) Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2(dimetilamino) etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol
BRPI0514221A (pt) composição fungicida contendo derivado de amida de ácido
BR112014025564A8 (pt) composto heterocíclico contendo nitrogênio ou sal do mesmo
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
WO2008135090A8 (en) Solid dosage forms comprising an enteric coating with accelerated drug release
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
PT2323972E (pt) Compostos de tetraciclina substituídos com c7-flúor
UY31736A (es) Derivados sustituidos de pirazol y su uso
BRPI0415053B8 (pt) inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
BR0312921A (pt) Composição compreendendo inibidor de reductase hmg-coa
BRPI0715698B8 (pt) produto, composição farmacêutica que o contém e uso de composto
WO2011025982A3 (en) Tetracycline compounds
BRPI0515582A (pt) 3-(2-hidroxifenil)pirazóis e seu uso como moduladores de hsp90
WO2011123536A8 (en) Polycyclic tetracycline compounds
EP1714961A4 (en) INDAZOL COMPOUND AND THEIR PHARMACEUTICAL USE
BR112015014292A2 (pt) compostos tricíclicos para inibição do canal de cftr
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
MXPA05011276A (es) Derivado heterociclico de cinco miembros.
ECSP22054240A (es) Compuesto y composici?n como inhibidor de quinasa del receptor pdgf

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.